Casebia Therapeutics Appoints Amy Jennings to Head its Regulatory Affairs
CAMBRIDGE, Mass., May 29, 2018 – Casebia Therapeutics, a biopharmaceutical company dedicated to the creation of life-transforming therapeutics through gene-editing technology, has appointed Amy Jennings, Ph.D., as its head of Regulatory Affairs.
Dr. Jennings brings over 15 years experience in global regulatory affairs, including leadership positions in some of the world’s leading biopharmaceutical companies. At Casebia, she will be responsible for developing regulatory strategy across the company’s portfolio. She will serve on Casebia’s Executive Leadership Team.
“Amy brings a depth of experience that we believe will be invaluable in formulating our product development and global regulatory strategies,” said James Burns, Ph.D., Casebia’s President and Chief Executive Officer. “She possesses deep regulatory expertise with a proven record of developing and executing on regulatory strategy. Her experience will be essential in accelerating our products into the clinic.”
Dr. Jennings regulatory experience encompasses drug development across multiple therapeutic realms, including diabetes, cardiovascular disease, obesity, viral infections and hematology.
She joins Casebia from Achillion Pharmaceuticals, where she was senior vice president and head of regulatory affairs. There, she was responsible for global regulatory strategy, regulatory operations, quality assurance, medical writing and pharmacovigilance. During her time at Achillion, Dr. Jennings led two successful IND submissions.
Earlier, Dr. Jennings served as Sanofi’s associate vice president for global regulatory affairs in the company’s North American diabetes program. At Sanofi she led a US and global regulatory affairs team and was also responsible for labeling and advertising/promotions.
Before Sanofi, Dr. Jennings held positions of increasing responsibility at Bristol-Myers Squibb, including leadership of US regulatory affairs for its cardiovascular/metabolics programs. She was ultimately group director in global regulatory affairs for special products. During her tenure at BMS, Dr. Jennings headed US regulatory efforts that led to the approval of two new diabetes drugs.
Amy was a post-doctoral fellow at the Harvard-affiliated Joslin Diabetes Center. She received her Ph.D. in Chemistry from The Ohio State University and her Bachelor of Science in Chemistry from the University of Wisconsin-Madison.
About Casebia Therapeutics
Casebia Therapeutics is a novel joint venture between Bayer and CRISPR Therapeutics, focused on discovering, developing and commercializing CRISPR/Cas9 gene-editing therapeutics to treat the genetic causes of bleeding disorders, autoimmune disease, blindness, hearing loss and heart disease. Launched in March 2016, Casebia has access to gene-editing technology from CRISPR Therapeutics in specific disease areas, as well as access to protein engineering expertise and relevant disease know-how through Bayer. Casebia is a free-standing entity, equally owned by Bayer and CRISPR Therapeutics, with its own scientific leadership and management team. The company’s Board of Directors has equal composition from Bayer and CRISPR Therapeutics. Casebia’s primary base of research operations is in Cambridge, MA, with a second site in San Francisco, CA.
For more information, please visit www.casebia.com.